TIGIT and lung cancer: In the PVR-positive A427 lung cancer model, studies have demonstrated that therapeutic strategies targeting KIR2DL5+TIGIT+ NK cells achieve significantly greater efficacy when employing KIR2DL5 blockade compared to TIGIT blockade [212].